Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy

被引：75
作者：
Okumura, Hiroshi [1 ]
Uchikado, Yasuto [1 ]
Setoyama, Tetsuro [1 ]
Matsumoto, Masataka [1 ]
Owaki, Tetsuhiro [1 ]
Ishigami, Sumiya [1 ]
Natsugoe, Shoji [1 ]
机构：
[1] Kagoshima Univ, Grad Sch Med Sci, Dept Digest Surg Breast & Thyroid Surg, Kagoshima 8908520, Japan
来源：
SURGERY TODAY | 2014年 / 44卷 / 03期
关键词：
Esophageal squamous cell carcinoma; Chemoradiation therapy; Prediction; Biomarker; HEDGEHOG SIGNAL ACTIVATION; ENDOTHELIAL GROWTH-FACTOR; CANCER-PATIENTS; P53; PROTEIN; CYCLIN D1; PREOPERATIVE CHEMORADIOTHERAPY; PROGNOSTIC-SIGNIFICANCE; TRIMODALITY THERAPY; DNA-DAMAGE; EXPRESSION;
D O I：
10.1007/s00595-013-0580-y
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
This review summarizes and evaluates the literature regarding the biomarkers for predicting the response and/or prognosis of esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiation therapy (CRT). There are seven categories of molecules known to correlate with the response and/or prognosis: tumor suppressors (p53, p21), cell cycle regulators (Cyclin D1, CDC25B, 14-3-3sigma), DNA repair molecules (p53R2, ERCC1), drug resistance proteins [metallothionein (MT)], angiogenic factors (VEGF), molecules involved in cell proliferation/invasion/metastasis (Ki-67, COX-2) and hedgehog signaling molecules (Gli-1). Of the above molecules, the tumor suppressor p53 is expected to be a representative biomarker for predicting the response and prognosis. The cell cycle markers CDC25B and 14-3-3sigma have potential as response biomarkers independent of the p53 status. The DNA repair markers, p53R2 or ERCC1, angiogenic molecule (VEGF), and hedgehog signaling pathway factor Gli-1 also have potential to predict the response and prognosis of ESCC. However, there are still many unanswered questions with regard to predicting the clinical effects of neoadjuvant CRT.
引用
收藏
页码：421 / 428
页数：8
相关论文
共 52 条
[1]   Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature [J].
Backer, Marina V. ;
Hamby, Carl V. ;
Backer, Joseph M. .
TISSUE-SPECIFIC VASCULAR ENDOTHELIAL SIGNALS AND VECTOR TARGETING, PART A, 2009, 67 :1-27
[2]   Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy [J].
Bruecher, Bjoern L. D. M. ;
Keller, Gisela ;
Werner, Martin ;
Mueller, Ulrike ;
Lassmann, Silke ;
Cabras, Antonello Domenico ;
Fend, Falko ;
Busch, Raymonde ;
Stein, Hubert ;
Allescher, Hans-Dieter ;
Molls, Michael ;
Siewert, J. Ruediger ;
Hoefler, Heinz ;
Specht, Katja .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (01) :69-77
[3]   P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES [J].
CAELLES, C ;
HELMBERG, A ;
KARIN, M .
NATURE, 1994, 370 (6486) :220-223
[4]   14-3-3σ is required to prevent mitotic catastrophe after DNA damage [J].
Chan, TA ;
Hermeking, H ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1999, 401 (6753) :616-620
[5]   ANGIOGENIC FACTOR [J].
FURUKAWA, T ;
YOSHIMURA, A ;
SUMIZAWA, T ;
HARAGUCHI, M ;
AKIYAMA, S ;
FUKUI, K ;
ISHIZAWA, M ;
YAMADA, Y .
NATURE, 1992, 356 (6371) :668-668
[6]  
HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.bi.55.070186.004405
[7]  
Hironaka S, 2002, CLIN CANCER RES, V8, P124
[8]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[9]   Hedgehog signaling in animal development: paradigms and principles [J].
Ingham, PW ;
McMahon, AP .
GENES & DEVELOPMENT, 2001, 15 (23) :3059-3087
[10]  
John MJ, 1989, CANCER, V632, P397
123456